CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Developing a Canadian Real-World Evidence Action Plan Across the Drug Life Cycle

June 22, 2020
Canadian policy-makers face challenges with the number of drugs for rare indications and rapidly rising costs. In facing these challenges, decision-makers see real-world evidence (RWE) as an opportunity. Health Canada and CADTH recently announced the intent to co-develop an action plan to optimize the process for systematically using and integr...

Happy 100th Birthday, Dr. Maurice McGregor!

June 8, 2020
On March 24, Dr. Maurice McGregor turned 100. Dr. McGregor is affectionately known as the “grandfather of health technology assessment” in Canada. In 2014 CADTH acknowledged his enduring legacy and his immeasurable contributions to Canadian health care by establishing an award in his name. This award is presented annually to “rising stars” in t...

Does the Evidence Support the Hype Around Antiviral Treatments for COVID-19?

May 27, 2020
Media Advisory Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies. Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...

Patient Input and Clinical Experts: Zolgensma

May 26, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Zolgensma Generic name onasemnogene abeparvovec Manufacturer Novartis Pharmaceuticals Canada Inc. Indication(s) Spinal muscular atrophy (SMA), pediatrics Project Number SG0649-000 Call for pat...